Chronic Urticaria or Hives - Drug Pipeline Landscape, 2023
Description
Chronic Urticaria or Hives - Drug Pipeline Landscape, 2023
Urticaria is an itchy rash that appears on the skin. It may appear on one part of the body or be spread across large areas. Chronic urticaria is a mast cell-mediated condition characterized by the recurrent occurrence of urticaria and/or angioedema.
The welts that come with hives are caused by the release of immune system chemicals, such as histamine, into the bloodstream. The skin reaction may be triggered by heat or cold, sunlight, vibration, pressure on the skin, medical conditions, such as thyroid disease, infection, allergy, and cancer.
Symptoms of chronic hives includes batches of welts (wheals) that can arise anywhere on the body, welts that might be red, purple, or skin colored. Welts that vary in size, change shape, and appear and fade repeatedly, Itchiness (pruritus), which can be intense, painful swelling (angioedema) around the eyes, cheeks, or lips.
Doctors most often diagnose chronic urticaria by examining the rash. The tests include complete blood count, erythrocyte sedimentation rate and C reactive protein are important investigations for diagnosis of infections in urticaria.
The most common investigative treatments include antihistamines. These drugs ease itching, swelling and other allergy symptoms. Second-generation H1-antihistamines (e.g., cetirizine, loratadine, fexofenadine), taken regularly, are the first-line pharmacological treatment. Omalizumab given as a subcutaneous injection is a second-line adjunct therapy for CSU that is unresponsive to H1-antihistamines.
Symptoms can be eased through lifestyle changes and home remedies like comfortably cool shower or bath, wear loose, smooth-textured cotton clothing and protect your skin from the sun.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Chronic Urticaria or Hives treatment such as CT-P39, Dupilumab, LOU064, TEV-45779, Tezepelumab and others. Key players involved in the development of therapies to treat Chronic Urticaria or Hives are Amgen, Celltrion, Novartis Pharmaceuticals, Sanofi, Teva Pharmaceuticals USA and others. Eight drugs are under late-stage Phase III clinical trials and Nine drugs are in Phase II clinical trials and some other drugs are under Phase I, Phase 0 and Preclinical stages of development.
In December 2022, Allakos announced the proof-of-concept results of Lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria.
Report Highlights
Global Insight Service's, Chronic Urticaria or Hives - Drug Pipeline Landscape, 2023 report provides an overview of the Chronic Urticaria or Hives pipeline drugs. This report covers detailed insights on Chronic Urticaria or Hives drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Chronic Urticaria or Hives pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Urticaria is an itchy rash that appears on the skin. It may appear on one part of the body or be spread across large areas. Chronic urticaria is a mast cell-mediated condition characterized by the recurrent occurrence of urticaria and/or angioedema.
The welts that come with hives are caused by the release of immune system chemicals, such as histamine, into the bloodstream. The skin reaction may be triggered by heat or cold, sunlight, vibration, pressure on the skin, medical conditions, such as thyroid disease, infection, allergy, and cancer.
Symptoms of chronic hives includes batches of welts (wheals) that can arise anywhere on the body, welts that might be red, purple, or skin colored. Welts that vary in size, change shape, and appear and fade repeatedly, Itchiness (pruritus), which can be intense, painful swelling (angioedema) around the eyes, cheeks, or lips.
Doctors most often diagnose chronic urticaria by examining the rash. The tests include complete blood count, erythrocyte sedimentation rate and C reactive protein are important investigations for diagnosis of infections in urticaria.
The most common investigative treatments include antihistamines. These drugs ease itching, swelling and other allergy symptoms. Second-generation H1-antihistamines (e.g., cetirizine, loratadine, fexofenadine), taken regularly, are the first-line pharmacological treatment. Omalizumab given as a subcutaneous injection is a second-line adjunct therapy for CSU that is unresponsive to H1-antihistamines.
Symptoms can be eased through lifestyle changes and home remedies like comfortably cool shower or bath, wear loose, smooth-textured cotton clothing and protect your skin from the sun.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Chronic Urticaria or Hives treatment such as CT-P39, Dupilumab, LOU064, TEV-45779, Tezepelumab and others. Key players involved in the development of therapies to treat Chronic Urticaria or Hives are Amgen, Celltrion, Novartis Pharmaceuticals, Sanofi, Teva Pharmaceuticals USA and others. Eight drugs are under late-stage Phase III clinical trials and Nine drugs are in Phase II clinical trials and some other drugs are under Phase I, Phase 0 and Preclinical stages of development.
In December 2022, Allakos announced the proof-of-concept results of Lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria.
Report Highlights
Global Insight Service's, Chronic Urticaria or Hives - Drug Pipeline Landscape, 2023 report provides an overview of the Chronic Urticaria or Hives pipeline drugs. This report covers detailed insights on Chronic Urticaria or Hives drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Chronic Urticaria or Hives pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
110 Pages
- 1. Introduction
- 1.1 Chronic Urticaria or Hives - Pipeline Drugs, 2023 - Coverage
- 2. Disease Overview - Chronic Urticaria or Hives
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Chronic Urticaria or Hives - Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Clinical Stage Drugs - Phase III
- 5.1.1 AVT23
- 5.1.2 CT-P39
- 5.1.3 Dupilumab
- 5.1.4 LOU064
- 5.1.5 QGE031
- 5.1.6 SYN008 (China)
- 5.1.7 SYN008 (Global)
- 5.1.8 TEV-45779
- 5.2 Clinical Stage Drugs - Phase II
- 5.2.1 AK002
- 5.2.2 Benralizumab
- 5.2.3 CDX-0159
- 5.2.4 LP0190
- 5.2.5 SAR444671
- 5.2.6 ST-101
- 5.2.7 TAS5315
- 5.2.8 Tezepelumab
- 5.2.9 UB-221
- 5.3 Clinical Stage Drugs - Phase I
- 5.3.1 GI-301
- 5.3.2 OP2101
- 5.3.3 THB001
- 5.3.4 TLL018
- 5.4 Clinical Stage Drugs - Phase 0
- 5.4.1 Mepolizumab
- 5.5 Early Stage Drugs - Preclinical
- 5.5.1 BA 2101
- 5.5.2 KFRX04
- 5.5.3 Multipotent Mesenchymal Stem Cells
- 5.5.4 VB517
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 Allakos Inc
- 9.2 Alvotech
- 9.3 Amgen
- 9.4 AstraZeneca
- 9.5 Celldex Therapeutics
- 9.6 Celltrion
- 9.7 CSPC Baike (Shandong) Biopharmaceutical Co Ltd
- 9.8 GI Innovation
- 9.9 Hangzhou Highlightll Pharmaceutical Co Ltd
- 9.10 KeifeRx LLC
- 9.11 LEO Pharma
- 9.12 LUE Pharma Group Ltd
- 9.13 Mayo Clinic
- 9.14 Mirae Cell Bio Co Ltd
- 9.15 Novartis Pharmaceuticals
- 9.16 OrchestratePharma GmbH
- 9.17 Sanofi
- 9.18 Stero Biotechs Ltd
- 9.19 Synermore
- 9.20 Taiho Pharmaceutical Co Ltd
- 9.21 Teva Pharmaceuticals USA
- 9.22 Third Harmonic Bio, Inc
- 9.23 United BioPharma
- 9.24 ValenzaBio Inc
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11. Appendix
- List of Tables
- Table 1.1 Number of Products under Development by Chronic Urticaria or Hives
- Table 1.2 Number of Products under Development by Companies
- Table 1.3 Products under Development by Companies
- Table 1.4 Products by Targets
- Table 1.5 Products by Mechanism of Action
- Table 1.6 Products by Molecule Type
- Table 1.7 Products by Route of Administration
- Table 2.1 Clinical Trial Details - CT-P39/Celltrion
- Table 2.2 Clinical Trial Details - Dupilumab/Sanofi
- Table 2.3 Clinical Trial Details - LOU064/Novartis Pharmaceuticals
- Table 2.4 Clinical Trial Details - QGE031/Novartis Pharmaceuticals
- Table 2.5 Clinical Trial Details - SYN008 (Global)/Synermore
- Table 2.6 Clinical Trial Details - TEV-45779/Teva Pharmaceuticals USA
- Table 2.7 Clinical Trial Details - AK002/Allakos Inc
- Table 2.8 Clinical Trial Details - Benralizumab/AstraZeneca
- Table 2.9 Clinical Trial Details - CDX-0159/Celldex Therapeutics
- Table 2.10 Clinical Trial Details - SAR444671/Sanofi
- Table 2.11 Clinical Trial Details - ST-101/Stero Biotechs Ltd
- Table 2.12 Clinical Trial Details - SYN008 (China)/CSPC Baike (Shandong) Biopharmaceutical Co., Ltd
- Table 2.13 Clinical Trial Details - TAS5315 /Taiho Pharmaceutical Co., Ltd
- Table 2.14 Clinical Trial Details - Tezepelumab/Amgen
- Table 2.15 Clinical Trial Details - UB-221/United BioPharma
- Table 2.16 Clinical Trial Details - OP2101/OrchestratePharma GmbH
- Table 2.17 Clinical Trial Details - THB001/Third Harmonic Bio, Inc
- Table 2.18 Clinical Trial Details - TLL018/Hangzhou Highlightll Pharmaceutical Co., Ltd
- Table 2.19 Clinical Trial Details - Mepolizumab/GlaxoSmithKline
- Table 3.1 Regulatory Designations
- Table 4.1 Inactive Drugs
- Table 4.2 Discontinued Drugs
- List of Figures
- Figure 1.1 Number of Products under Development for Chronic Urticaria or Hives, 2023
- Figure 1.2 Products by Top 5 Targets and Stage of Development for Chronic Urticaria or Hives, 2023
- Figure 1.3 Products by Top 5 Mechanism of Action and Stage of Development for Chronic Urticaria or Hives, 2023
- Figure 1.4 Products by Top 5 Molecule Type and Stage of Development for Chronic Urticaria or Hives, 2023
- Figure 1.5 Products by Top 5 Route of Administration and Stage of Development for Chronic Urticaria or Hives, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
